[go: up one dir, main page]

AR097309A2 - Un proceso a gran escala para preparar un compuesto de éster aminobórico - Google Patents

Un proceso a gran escala para preparar un compuesto de éster aminobórico

Info

Publication number
AR097309A2
AR097309A2 ARP140103012A ARP140103012A AR097309A2 AR 097309 A2 AR097309 A2 AR 097309A2 AR P140103012 A ARP140103012 A AR P140103012A AR P140103012 A ARP140103012 A AR P140103012A AR 097309 A2 AR097309 A2 AR 097309A2
Authority
AR
Argentina
Prior art keywords
formula
ester compound
compound
defined above
solvent
Prior art date
Application number
ARP140103012A
Other languages
English (en)
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34968044&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR097309(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of AR097309A2 publication Critical patent/AR097309A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)

Abstract

Reivindicación 1: Un proceso a gran escala para preparar un compuesto de éster aminobórico de fórmula (3a) ó (3), o una sal de adición de ácidos del mismo, donde: R¹ es un grupo alifático, aromático o heteroaromático opcionalmente sustituido; y R⁴ y R⁵, tomados junto con los átomos de oxígeno y boro que intervienen, forman un éster bórico cíclico quiral opcionalmente sustituido; comprendiendo dicho proceso: (a) proporcionar un complejo boronato de fórmula (2a) ó (2b), donde Y es un grupo nucleófugo; M⁺ es un catión; R² es hidrógeno; R³ es un grupo nucleófugo; y R⁴ y R⁵ son como se han definido anteriormente; (b) poner en contacto el complejo boronato de fórmula (2a) ó (2b) con un ácido de Lewis en condiciones que dan un compuesto de éster bórico de fórmula (1a) ó (1b), donde cada uno de R¹ a R⁵ es como se ha definido anteriormente, realizándose dicha etapa de puesta en contacto en a mezcla de reacción que comprende: (i) un disolvente de coordinación de éter que tiene una baja miscibilidad con agua; o (ii) un disolvente de éter que tiene una baja miscibilidad con agua y un co-disolvente de coordinación; (c) tratar el compuesto de éster bórico de fórmula (1a) ó (1b) con un reactivo de fórmula M¹-N(G)₂, donde M¹ es un metal alcalino y cada G es un resto protector del grupo amino, para formar un compuesto de fórmula (4a) ó (4b), donde cada G y R¹ a R⁵ son como se han definido anteriormente; y (d) retirar los grupos G para formar un compuesto de fórmula (3a) ó (3b), o una sal de adición de ácidos del mismo.
ARP140103012A 2004-03-30 2014-08-11 Un proceso a gran escala para preparar un compuesto de éster aminobórico AR097309A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55753504P 2004-03-30 2004-03-30

Publications (1)

Publication Number Publication Date
AR097309A2 true AR097309A2 (es) 2016-03-02

Family

ID=34968044

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP050101205A AR049374A1 (es) 2004-03-30 2005-03-30 Sintesis de compuestos de ester y acido borico
ARP140103012A AR097309A2 (es) 2004-03-30 2014-08-11 Un proceso a gran escala para preparar un compuesto de éster aminobórico
ARP140103013A AR097310A2 (es) 2004-03-30 2014-08-11 Síntesis de compuestos de éster y ácido bórico

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP050101205A AR049374A1 (es) 2004-03-30 2005-03-30 Sintesis de compuestos de ester y acido borico

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP140103013A AR097310A2 (es) 2004-03-30 2014-08-11 Síntesis de compuestos de éster y ácido bórico

Country Status (41)

Country Link
US (14) US7714159B2 (es)
EP (5) EP2377868A1 (es)
JP (4) JP4558039B2 (es)
KR (1) KR100939598B1 (es)
CN (5) CN111925385B (es)
AR (3) AR049374A1 (es)
AT (1) ATE521612T1 (es)
AU (1) AU2005230930B2 (es)
BR (1) BRPI0509587A (es)
CA (4) CA2738706C (es)
CL (2) CL2010000350A1 (es)
CR (1) CR8653A (es)
CY (3) CY1112053T1 (es)
DK (4) DK1756121T3 (es)
DO (1) DOP2011000293A (es)
EA (1) EA012927B1 (es)
EC (1) ECSP066960A (es)
ES (4) ES2974758T3 (es)
FI (1) FI4008721T3 (es)
HK (1) HK1246300A1 (es)
HR (4) HRP20240307T3 (es)
HU (2) HUE065769T2 (es)
IL (3) IL178250A (es)
LT (2) LT3385267T (es)
ME (1) ME01975B (es)
MX (1) MX367324B (es)
MY (1) MY145427A (es)
NL (3) NL1028639C2 (es)
NO (4) NO338905B1 (es)
NZ (3) NZ550522A (es)
PE (3) PE20110075A1 (es)
PL (4) PL4008721T3 (es)
PT (4) PT1756121E (es)
RS (4) RS51983B (es)
SG (5) SG10201600029PA (es)
SI (4) SI1756121T1 (es)
TW (1) TWI386212B (es)
UA (1) UA90108C2 (es)
UY (3) UY28830A1 (es)
WO (1) WO2005097809A2 (es)
ZA (1) ZA200608689B (es)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
DK1756121T3 (da) 2004-03-30 2012-01-09 Millennium Pharm Inc Syntese af borester- og borsyreforbindelser
WO2008075376A1 (en) * 2006-12-18 2008-06-26 Natco Pharma Limited Polymorphic forms of bortezomib and process for their preparation
WO2009004350A1 (en) * 2007-07-03 2009-01-08 Pliva Hrvatska D.O.O. Methods for preparing bortezomib and intermediates used in its manufacture
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
AU2016253697A1 (en) * 2007-08-06 2016-11-24 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
EA034601B1 (ru) * 2007-08-06 2020-02-25 Милленниум Фармасьютикалз, Инк. Способ получения бороновых кислот
NZ582693A (en) * 2007-08-06 2012-01-12 Millennium Pharm Inc Boron-containing proteasome inhibitors
WO2009026579A1 (en) * 2007-08-23 2009-02-26 Cornell Research Foundation, Inc. Proteasome inhibitors and their use in treating pathogen infection and cancer
AU2008298694A1 (en) * 2007-09-12 2009-03-19 Dr. Reddy's Laboratories Ltd. Bortezomib and process for producing same
US7838673B2 (en) 2007-10-16 2010-11-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
SG194349A1 (en) 2008-06-17 2013-11-29 Millennium Pharm Inc Boronate ester compounds and pharmaceutical compositions thereof
AU2013204889A1 (en) * 2008-09-29 2013-05-16 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclobutylethylboronic acid
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
EP2238973A1 (en) 2009-04-07 2010-10-13 Cephalon France Lyophilized preparations of proteasome inhibitors
CN101899062B (zh) * 2009-05-26 2015-04-15 上海威智医药科技有限公司 α-手性硼酸及硼酸酯的合成工艺
EP2270019A1 (en) 2009-06-19 2011-01-05 LEK Pharmaceuticals d.d. New synthetic route for the preparation of alpha-amino boronic esters
US9315525B2 (en) 2009-06-19 2016-04-19 Lek Pharmaceuticals D.D. Synthetic route for the preparation of α-amino boronic acid derivatives via substituted alk-1-ynes
EP2280016A1 (en) 2009-07-27 2011-02-02 LEK Pharmaceuticals d.d. New synthetic route for the preparation of alpha-amino boronic esters via substituted alk-1-ynes
AU2010341530B2 (en) 2009-12-22 2016-03-10 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
US20110178287A1 (en) 2010-01-19 2011-07-21 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
US20130085277A1 (en) 2010-02-09 2013-04-04 Ranbaxy Laboratories Limited Process for the preparation of bortezomib
CN101781326B (zh) * 2010-02-11 2013-08-21 福建南方制药股份有限公司 一种制备手性氨基硼酸的中间体及其制备方法
WO2011107912A1 (en) 2010-03-04 2011-09-09 Ranbaxy Laboratories Limited Polymorphic forms of bortezomib
AU2011227083B2 (en) * 2010-03-18 2013-07-18 Innopharma, Inc. Stable bortezomib formulations
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
EA029521B1 (ru) 2010-03-31 2018-04-30 Милленниум Фармасьютикалз, Инк. Производные 1-амино-2-циклопропилэтилбороновой кислоты
CN101812026B (zh) * 2010-04-12 2013-08-28 亚邦医药股份有限公司 一种硼替佐米的合成方法
CN105797168A (zh) 2010-05-18 2016-07-27 天蓝制药公司 用于治疗自身免疫性疾病或其它疾病的组合物和方法
US8884009B2 (en) 2010-10-14 2014-11-11 Synthon Bv Process for making bortezomib and intermediates for the process
TW201309303A (zh) 2011-03-03 2013-03-01 Cephalon Inc 用於治療狼瘡的蛋白酶體抑制劑
CN102206188B (zh) * 2011-04-08 2013-02-27 苏州二叶制药有限公司 N-(吡嗪-2-基羰基)-l-苯丙氨酸的制备方法
US8497374B2 (en) 2011-05-12 2013-07-30 Scinopharm Taiwan, Ltd. Process for preparing and purifying bortezomib
CN102268029B (zh) * 2011-05-19 2013-10-09 苏州二叶制药有限公司 化合物（1s,2s,3r,5s）-蒎烷二醇-l-苯丙氨酸-l-亮氨酸硼酸酯的制备
MX2013015308A (es) 2011-06-22 2014-05-20 Cephalon Inc Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso.
CN102351890B (zh) * 2011-09-30 2014-07-02 重庆泰濠制药有限公司 一种硼替佐米的合成方法
CN102492021B (zh) * 2011-12-13 2013-10-23 重庆泰濠制药有限公司 硼替佐米的制备工艺
JP6129203B2 (ja) * 2011-12-22 2017-05-17 アレス トレーディング ソシエテ アノニム α−アミノボロン酸誘導体、選択性免疫プロテアソーム阻害剤
CN103374026A (zh) * 2012-04-27 2013-10-30 重庆医药工业研究院有限责任公司 一种硼替佐米中间体的制备方法
CN103450331B (zh) * 2012-06-05 2016-05-25 山东新时代药业有限公司 一种硼替佐米的精制方法
JP2015532915A (ja) 2012-09-11 2015-11-16 シプラ・リミテッド ボルテゾミブの製造方法
WO2014072985A1 (en) 2012-11-06 2014-05-15 Natco Pharma Limited Novel boronic acid derivatives as anti cancer agents
CA2891822A1 (en) 2012-11-16 2014-05-22 Shilpa Medicare Limited Crystalline bortezomib process
RU2654692C2 (ru) 2012-12-07 2018-05-22 Венаторкс Фармасьютикалс, Инк. Ингибиторы бета-лактамаз
CN103897026A (zh) * 2012-12-29 2014-07-02 朱继东 硼替佐米关键中间体的晶型，制备方法及其运用
CN103897027A (zh) * 2012-12-29 2014-07-02 曹亚英 关键中间体晶型，制备方法及其在硼替佐米合成中的运用
EP2943204B1 (en) 2013-01-10 2019-03-13 Venatorx Pharmaceuticals Inc Beta-lactamase inhibitors
ZA201402789B (en) 2013-04-16 2015-11-25 Cipla Ltd Process for the preparation of bortezomib mannitol ester
CN104211758B (zh) * 2013-05-29 2020-06-12 深圳翰宇药业股份有限公司 一种硼替佐米的制备方法
CN103497233B (zh) * 2013-09-30 2015-04-08 哈药集团技术中心 一种硼替佐米的制备方法
CN103554219A (zh) * 2013-10-01 2014-02-05 昆明贵研药业有限公司 一种制备硼替佐米的方法
KR101691353B1 (ko) * 2013-12-09 2016-12-30 주식회사 경보제약 보르테조밉의 제조방법 및 그의 신규 중간체
EP3102585B1 (en) 2014-02-03 2021-05-19 Ohio State Innovation Foundation Boronic acid esters and pharmaceutical formulations thereof
CR20160577A (es) 2014-05-20 2017-01-06 Millennium Pharm Inc Inhibidores de proteasoma que contienen boro para usarse despues de una terapia de cancer primaria
CA2950917C (en) 2014-06-11 2022-08-23 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
JP6420629B2 (ja) * 2014-10-30 2018-11-07 ボーグワーナー インコーポレーテッド チェーンガイドおよびチェーンテンショナアーム
DE102015204151B4 (de) * 2015-03-09 2025-12-24 Adidas Ag Ball, insbesondere Fußball, und Verfahren zur Herstellung eines Balls
JP6223508B2 (ja) * 2016-06-27 2017-11-01 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤
WO2018027062A1 (en) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
KR20190127681A (ko) * 2017-02-17 2019-11-13 프레세니어스 카비 온콜로지 리미티드 붕소산 에스테르의 개선된 제조방법
CN110678186A (zh) 2017-03-06 2020-01-10 维纳拓尔斯制药公司 包含β-内酰胺酶抑制剂的固体形式和组合式组合物及其用途
CN110959008A (zh) 2017-05-26 2020-04-03 维纳拓尔斯制药公司 青霉素结合蛋白抑制剂
WO2018218154A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2019020099A1 (zh) 2017-07-28 2019-01-31 成都地奥九泓制药厂 一种硼酸酯化合物、其合成方法及其用途
CN111065641A (zh) 2017-09-02 2020-04-24 太阳制药工业有限公司 柠檬酸伊沙佐米的制备方法
US12173018B2 (en) 2018-05-25 2024-12-24 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
CN111187336B (zh) * 2018-11-14 2022-05-20 正大天晴药业集团股份有限公司 硼替佐米的精制方法
US11964993B2 (en) 2021-07-03 2024-04-23 Shilpa Pharma Lifesciences Limited Crystalline bortezomib process
WO2025034812A2 (en) 2023-08-07 2025-02-13 Tae Life Sciences Llc Trifluoroborate (bf3) compositions for use in boron neutron capture therapy and methods thereof
WO2025080942A1 (en) * 2023-10-13 2025-04-17 The Brigham And Women’S Hospital, Inc. Proteasome inhibitors and methods of use thereof
CN120248757A (zh) * 2025-05-28 2025-07-04 滁州瑞达新能源材料有限公司 一种自清洁耐候的铝合金光伏组件边框及其制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL31992A (en) * 1968-05-08 1973-07-30 American Cyanamid Co Synthetic thyrocalcitonins and method of making them
ZA794723B (en) * 1978-09-11 1980-08-27 Univ Miami Anti-hypertensive agents
US4525309A (en) * 1983-03-15 1985-06-25 Washington State University Research Foundation, Inc. Lewis acid catalysis of the homologation of boronic esters with haloalkylmetal reagents
US4537773A (en) 1983-12-05 1985-08-27 E. I. Du Pont De Nemours And Company α-Aminoboronic acid derivatives
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
ES542440A0 (es) * 1985-04-22 1985-12-16 Inke Sa "procedimiento para la obtencion del ester benzilico de 1-(n-(1--etoxicarbonil-3-oxo-fenilpropil)-l-alanil)-l-prolina".
SE8506094D0 (sv) * 1985-12-20 1985-12-20 Astra Laekemedel Ab New antibacterial agents and intermediates therefor
US4701545A (en) * 1986-02-12 1987-10-20 Washington State University Research Foundation, Inc. Preparation of α,α-dihaloalkyl boronic esters
US5250720A (en) * 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
US5242904A (en) * 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (de) * 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
US5106948A (en) * 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
EP2251344B2 (en) * 2001-01-25 2024-04-24 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Formulation of boronic acid compounds
JPWO2003033506A1 (ja) * 2001-10-12 2005-02-03 杏林製薬株式会社 アミノボラン酸誘導体およびそれを含有するプロテアソーム阻害薬
WO2003033507A1 (en) 2001-10-12 2003-04-24 Kyorin Pharmaceutical Co., Ltd. Benzylmalonic acid derivatives and proteasome inhibitors contaiing the same
DK1756121T3 (da) 2004-03-30 2012-01-09 Millennium Pharm Inc Syntese af borester- og borsyreforbindelser
WO2009004350A1 (en) * 2007-07-03 2009-01-08 Pliva Hrvatska D.O.O. Methods for preparing bortezomib and intermediates used in its manufacture
US7838673B2 (en) * 2007-10-16 2010-11-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
US9315525B2 (en) * 2009-06-19 2016-04-19 Lek Pharmaceuticals D.D. Synthetic route for the preparation of α-amino boronic acid derivatives via substituted alk-1-ynes

Also Published As

Publication number Publication date
HRP20110846T1 (hr) 2011-12-31
JP2007530687A (ja) 2007-11-01
ME01975B (me) 2015-05-20
US20220204558A1 (en) 2022-06-30
PT3385267T (pt) 2021-11-23
WO2005097809A2 (en) 2005-10-20
SG10201600029PA (en) 2016-02-26
CN107474062A (zh) 2017-12-15
JP6193960B2 (ja) 2017-09-06
CN103396427B (zh) 2018-04-13
NZ598172A (en) 2013-08-30
EP2377869A1 (en) 2011-10-19
UY28830A1 (es) 2005-09-30
US20050240047A1 (en) 2005-10-27
SI3385267T1 (sl) 2022-04-29
CA2853272A1 (en) 2005-10-20
CN103396427A (zh) 2013-11-20
PT1756121E (pt) 2011-11-30
EP3385267A1 (en) 2018-10-10
UY35578A (es) 2016-01-08
HRP20240307T3 (hr) 2024-05-10
AR049374A1 (es) 2006-07-26
EP2377868A1 (en) 2011-10-19
PE20110075A1 (es) 2011-02-17
NL1033189C2 (nl) 2008-08-14
US20180265546A1 (en) 2018-09-20
US10000529B2 (en) 2018-06-19
HK1257298A1 (zh) 2019-10-18
NZ586824A (en) 2012-03-30
EP4008721A1 (en) 2022-06-08
SG182998A1 (en) 2012-08-30
US20210395301A1 (en) 2021-12-23
KR20070007873A (ko) 2007-01-16
AU2005230930B2 (en) 2011-09-29
CA2738706A1 (en) 2005-10-20
EP2377869B1 (en) 2014-01-29
NO344610B1 (no) 2020-02-10
CY1124753T1 (el) 2022-07-22
IL219856A0 (en) 2012-06-28
UA90108C2 (uk) 2010-04-12
TWI386212B (zh) 2013-02-21
RS53259B (sr) 2014-08-29
EP1756121B1 (en) 2011-08-24
US20160362449A1 (en) 2016-12-15
WO2005097809A3 (en) 2006-02-16
DK4008721T3 (da) 2024-03-25
CN111925385B (zh) 2023-11-21
PE20142402A1 (es) 2015-02-04
AU2005230930A1 (en) 2005-10-20
AR097310A2 (es) 2016-03-02
EP1756121A2 (en) 2007-02-28
US20210171574A1 (en) 2021-06-10
MX367324B (es) 2019-08-15
EP3385267B1 (en) 2021-09-29
KR100939598B1 (ko) 2010-02-01
NL1033190A1 (nl) 2007-04-23
CY1112053T1 (el) 2015-11-04
CA2560886A1 (en) 2005-10-20
NZ550522A (en) 2010-08-27
JP5414625B2 (ja) 2014-02-12
SG182999A1 (en) 2012-08-30
UY34969A (es) 2015-02-27
LT4008721T (lt) 2024-03-25
PL3385267T3 (pl) 2022-02-14
LT3385267T (lt) 2021-11-10
NL1033190C2 (nl) 2007-11-27
US9862745B2 (en) 2018-01-09
BRPI0509587A (pt) 2007-09-25
FI4008721T3 (fi) 2024-03-19
NL1033189A1 (nl) 2007-10-22
ECSP066960A (es) 2006-12-20
JP2010241816A (ja) 2010-10-28
IL219853A0 (en) 2012-06-28
HUE065769T2 (hu) 2024-06-28
US20190112334A1 (en) 2019-04-18
SI2377869T1 (sl) 2014-05-30
HK1246300A1 (zh) 2018-09-07
ES2974758T3 (es) 2024-07-01
CA2859119A1 (en) 2005-10-20
DK3385267T3 (da) 2021-11-01
CL2010000350A1 (es) 2011-01-28
US8283467B2 (en) 2012-10-09
NO20064893L (no) 2006-12-22
JP4558039B2 (ja) 2010-10-06
PE20060162A1 (es) 2006-04-07
JP2016056180A (ja) 2016-04-21
NL1028639C2 (nl) 2007-01-17
RS51983B (sr) 2012-02-29
US20130005968A1 (en) 2013-01-03
PL1756121T3 (pl) 2012-02-29
DOP2011000293A (es) 2011-12-15
CA2738706C (en) 2014-10-14
SG151322A1 (en) 2009-04-30
US7714159B2 (en) 2010-05-11
CN1960996B (zh) 2016-04-20
JP5894952B2 (ja) 2016-03-30
PL2377869T3 (pl) 2014-07-31
DK1756121T3 (da) 2012-01-09
US20150038706A1 (en) 2015-02-05
NO20161350A1 (no) 2006-12-22
US20100174072A1 (en) 2010-07-08
US20180044377A1 (en) 2018-02-15
US20190330270A1 (en) 2019-10-31
PT2377869E (pt) 2014-04-15
SI1756121T1 (sl) 2012-03-30
PT4008721T (pt) 2024-03-21
ATE521612T1 (de) 2011-09-15
US20200157143A1 (en) 2020-05-21
HK1164320A1 (en) 2012-10-19
EA200601795A1 (ru) 2007-04-27
CN108329337B (zh) 2021-06-25
SI4008721T1 (sl) 2024-05-31
RS62738B1 (sr) 2022-01-31
NO338905B1 (no) 2016-10-31
HUE056859T2 (hu) 2022-03-28
ES2371652T3 (es) 2012-01-05
IL219856A (en) 2015-05-31
ZA200608689B (en) 2007-09-26
CN111925385A (zh) 2020-11-13
TW200616646A (en) 2006-06-01
EP4008721B1 (en) 2024-01-03
CA2560886C (en) 2014-08-12
EA012927B1 (ru) 2010-02-26
HRP20140339T1 (hr) 2014-05-09
NO343966B1 (no) 2019-07-29
DK2377869T3 (da) 2014-04-14
IL178250A0 (en) 2006-12-31
CY1115336T1 (el) 2017-01-04
SG10201800972PA (en) 2018-03-28
CR8653A (es) 2007-10-23
IL178250A (en) 2012-06-28
ES2457593T3 (es) 2014-04-28
ES2899606T3 (es) 2022-03-14
JP2013100378A (ja) 2013-05-23
NL1028639A1 (nl) 2005-10-20
HRP20212002T1 (hr) 2022-04-01
CN1960996A (zh) 2007-05-09
NO20191065A1 (no) 2006-12-22
HK1100004A1 (en) 2007-08-31
US20200369722A1 (en) 2020-11-26
NO20171939A1 (no) 2006-12-22
CN108329337A (zh) 2018-07-27
RS65253B1 (sr) 2024-03-29
MY145427A (en) 2012-02-15
CL2014002252A1 (es) 2014-12-05
PL4008721T3 (pl) 2024-05-13
IL219853A (en) 2015-05-31

Similar Documents

Publication Publication Date Title
AR097309A2 (es) Un proceso a gran escala para preparar un compuesto de éster aminobórico
Thomas et al. Elucidating the role of the boronic esters in the Suzuki–Miyaura reaction: structural, kinetic, and computational investigations
AR079491A1 (es) Metodos de sintesis de inhibidores del factor xa tal como el betrixaban y composiciones farmaceuticas que contienen la base libre de betrixaban o su sal sustancialmente pura.
ES8705387A1 (es) Un procedimiento para preparar derivados de n-aril-n-(4-piperidinil)-alcoxialquilamida
ES8507480A1 (es) Un metodo para producir un derivado de amina
ES2254047T1 (es) Procedimiento de preparacion de derivados de topiramato anticonvulsivos.
AR095018A1 (es) Procesos e intermedios para hacer un inhibidor de jak
BR112012008939A2 (pt) processo para a preparação de compostos úteis como inibidores de sglt2
ES8303329A1 (es) Procedimiento para la obtencion de acidos 1-carboxi-(azaal- canoil o azaaralcanoil)-indolin-2-carboxilicos.
AR092070A1 (es) Proceso para la preparacion de inhibidores de quinasa c-fms
ES482252A1 (es) Un procedimiento para la produccion de un acito 7-amino (sustituido)-3-(tiometil sustituido)d3-cefem-4-carboxilico.
ATE671T1 (de) Verfahren zum aufloesen organischer oder mineraler salze in organischen loesungsmitteln und komplexe organischer oder mineraler salze.
ES8607960A1 (es) Procedimiento para preparar acidos aroil-benzofuran y benzo-tiofen-aceticos y-propionicos
AR121075A1 (es) Proceso químico
AR087072A1 (es) Procesos para la preparacion de tietanamina
ES8105993A1 (es) Un procedimiento para la preparacion de fenil-quinolicidinas
ES471809A1 (es) Procedimiento para preparar derivados de naftaleno
ES8304140A1 (es) Procedimiento para preparar derivados de cefalosporina.
MX3388E (es) Procedimiento para la preparacion de homoftalimidas
ES8403891A1 (es) Un procedimiento para la preparacion de un derivado del acido furiloxazolila-cetico
BR0208921A (pt) Processo para produção de derivados alcoólicos
AR092071A1 (es) Proceso para la preparacion de derivados de ester heterociclicos
ES440831A1 (es) Un procedimiento de obtencion de nuevos acidos bencilamino alcanoicos.
MX3393E (es) Procedimiento para la preparacion de arilalcohilaminas
Choudhary Development of Amine-Boranes And Derivatives For Reductive Amination. pdf

Legal Events

Date Code Title Description
FG Grant, registration